ArticleG3 (Bethesda, Md.)2018
Inducible Genome Editing with Conditional CRISPR/Cas9 Mice.
Article in G3 (Bethesda, Md.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Generation ofJBMR plus · 2026Article
- Stage- and tissue-specific gene editing using 4-OHT-inducible Cas9 in whole organism.The Journal of cell biology · 2026Article
- Recent advances in CRISPR technologies for biomedical applications and disease treatment.Theranostics · 2026Review
- Development and characterisation of improved unifocal primary mouse lung cancer models with metastatic potential.The Journal of pathology · 2025Article
- Massively parallel in vivo Perturb-seq screening.Nature protocols · 2025Review
- A CRISPR view of hematopoietic stem cells: Moving innovative bioengineering into the clinic.American journal of hematology · 2022Review
- CRISPR somatic genome engineering and cancer modeling in the mouse pancreas and liver.Nature protocols · 2022Review
- Drug discovery oncology in a mouse: concepts, models and limitations.Future science OA · 2021Review
- Forward and Reverse Genetics of B Cell Malignancies: From Insertional Mutagenesis to CRISPR-Cas.Frontiers in immunology · 2021Review
- Development of an ObLiGaRe Doxycycline Inducible Cas9 system for pre-clinical cancer drug discovery.Nature communications · 2020Article
- Endothelial mechanobiology.APL bioengineering · 2020Article
- Animal Models to Study Cancer and Its Microenvironment.Advances in experimental medicine and biology · 2020Review
- A Tet/Q Hybrid System for Robust and Versatile Control of Transgene Expression in C. elegans.iScience · 2019Article
- Chemical Biology Gateways to Mapping Location, Association, and Pathway Responsivity.Frontiers in chemistry · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genetically engineered mouse models (GEMMs) are powerful tools by which to probe gene function
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.